Latest News - 康诺亚生物医药科技成都有限公司

CN

Latest News Media

News

More

Keymed Biosciences and Rona Therapeutics Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis

Keymed Biosciences ( "Keymed ", HKEX: 02162) and Rona Therapeutics, Inc (“Rona”), today announced a collaboration to

2023-05-15
More

PRIMARY STUDY ENDPOINTS FROM PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN ADULTS

CHENGDU, China, March 28, 2023 – Keymed Biosciences Inc , (“Keymed”) (Stock Code: 02162 HK) is pleased to anno

2023-03-28
More

Keymed Biosciences Announces 2022 Annual Results

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Globa

2023-03-17
More

Keymed and InnoCare Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody CM369

Keymed Biosciences and InnoCare Pharma jointly announced today that the first subject has been dosed in clinical trial of CM369 (ICP-B05), an anti-C...

2023-02-24
More

Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

KYM Biosciences, the joint venture established by Keymed and Lepu Biopharma, on transaction closing and additional development and sales-related milestone payments of up to $1 1bn as well as tiered royalties up to low double-digits

2023-02-23
More

CM310 was granted Breakthrough Therapy Designation by the CDE for the treatment of moderate to severe atopic dermatitis

CHENGDU, China, June 15, 2022 – Keymed Biosciences (HKEX: 02162) is pleased to announce that the Center for Drug Eval

2022-06-15
More

Keymed Biosciences announces dosing of first patient in Phase I trial of bispecific antibody CM350

CHENGDU, China, June 9, 2022 – Keymed Biosciences (HKEX: 02162) announced today that the first patienthas been d

2022-06-09
$FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies$

More

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

April, 2022 – Keymed Biosciences (HKEX:02162) announced that the U S Food and Drug Administration (FDA) granted CMG

2022-04-19
More

CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the FDA

Keymed Biosciences announced that its new drug candidate CMG901 (the “Claudin 18 2 antibody drug conjugates”) for

2022-04-11

14条上一页 1 2 下一页